Medisun and Tsinghua University starting collaboration

The founding of Enterprise Fund for the Tsinghua University and Medisun Cell Technological Research and Regenerative Medicine

In April 26, 2017 Medisun Medical Group and Tsinghua University held a signing ceremony, formally announced the establishment of the “Tsinghua Medisun Cell Technology Research Institute” and setting up the “Tsinghua Medisun Cell Technology and Regenerative Enterprise Investment Fund”. At the time of the 106th anniversary of Tsinghua University, the signing ceremony was presided by the prof. Dong Chen, Dean of the School of medicine, Tsinghua University, with the signing officials, the Chairman of Medisun Medical Group Mr. Danny Wong, The Executive Director of Medisun Medical Group Dr. Wen Feng, Vice President of Tsinghua University and the Chairman of Tsinghua University Education Foundation Yang Bin, Tsinghua University Education Foundation Secretary-General Li Jiaqiang, Medical School’s party secretary Hongbo and many other college leaders attended the signing ceremony.

The signing parties: Tsinghua University School of Medicine Dong Chen and Medisun Medical Group Chairman Danny Wong

The global leading platform of Regenerative Medicine on Cell Technology : The Enterprise Fund for the Cell Technological Research and Regenerative Medicine is based on the advance technology, professional staffing, skill proficiency, resources and management experience of the Medisun Medical Group. Further enhanced by the quality and scientific research platform offered by the Tsinghua University, for the collaboration with the School of Medicine and the Tsinghua Chang Gung Memorial Hospital and other affiliated institutions. To focus on cell technology and cell therapy in the area of education, training, scientific research, clinical transformation and industrial development. Through the combination of the above strong elements, to reinforce the professional leadership of the School of Medicine of Tsinghua University.

The two parties will actively cooperate with the integration of professionals and the high-quality resources, to build the institute as:
* The world’s leading cell technology platform to support the training of professionals
* The world’s leading cell technology platform for research, development and clinical transformation
* The world’s leading platform for international cooperation for development of cell technology
* China as the most influential authority on cell technology and related laws, regulations and operational standards

Cell Technology and Regenerative Medicine Enterprise Investment Fund

At the time of setting up the research institute, Tsinghua University and Medisun Medical Group, National Investment Funds Limited (The Directors of Medisun Medical Group) also co-sponsored the establishment of Tsinghua Medisun Cell Technology and Regenerative Enterprise Investment Fund. The movement will attract more financial ventures to participate and invest the technology for further research, development and clinical transformation. The increase of the social capital can increase the investment in scientific research, and reduce the burden on the government and university’s expenses. This is to ensure the scientific research is carried out normally, to achieve the scientific research objectives. Secondly, the investment from the enterprise can motivate the research staff for better efficiency of the scientific research and to enhance the productivity. Thereby to enhance the brand value and social benefits.

The Enterprise Investment Fund will be included in the Tsinghua University School of Medicine’s overall industrial strategy. According to the management standard of the School of medicine, it will be used for the research and development, and clinical transformation with the Tsinghua Chang Gung Memorial Hospital, to accomplish the combination of leap forward development strategy. At the same time, to set up a 10 years plan on the Enterprise Investment Fund. The profit from the operating outcome will donate to the Institute for teaching, research and related charity projects to promote the cell technology and regenerative medicine for an sustainable development.

Life Science – a main agenda on the 13th Five – year Plan

Life science is one of the most rapid developing area of the twentieth century and become one of the most striking discipline of natural life science. From the early stage of the development of the cell technology and cell therapy has already heading a medical revolution. In compare with the traditional drug therapy and surgery, the cell technology has develop a new means as the third choice of treatment. With advance improvement, it can has a broad market and potential for further expansion. The General Secretary Xi Jinping pointed out at the National Science and Technology Innovation Conference that stem cell research, early diagnosis of cancer markers, human genome sequencing and other basic scientific breakthroughs, all these can become an influential factors for China to face the world. Enterprises place an important force for integration of science, technology and economic growth. As the investment on research, development and transformation will become the main drive of the technological innovation. To adjust the existing industry and local research institutions, enrich enterprise R & D strength, support enterprises to build national technology and innovation center, cultivate the industry which could become the business pioneer. The collaboration between Medisun and Tsinghua University is a strong response to the National thirteen five years plan’s development direction, and to create a comprehensive platform for research and development.

The cooperation with the Medisun and Tsinghua University will lead the growth of cell technology and cell therapy in China. This will further promote the establishment of a comprehensive laws and regulation on cellular technology, industry standards, norms, system for cultivation and high-end and quality scientific research. Also training of medical personnel, support the international exchanges, enhance the ability of independent innovation by building a world class cell technology and cell therapy transformation platform. Then China will own the world high-end standard expertise and transformation cell technology enterprise. See more details on http://www.medisun.hk/.